In a murine melanoma model, the combination of melanocortin 1 receptor (MC1R)-targeted 212Pb-VMT01 with immune checkpoint inhibitors (ICIs; anti-CTLA-4 and anti-PD-1) proved superior in inhibiting tumour growth compared to treatment alone. Here, PDCD1 is linked to melanoma.